Cargando…

Timing of Hepatitis B Vaccine Birth Dose in Exposed Newborns, Southwest Ethiopia: A Cross-Sectional Study

INTRODUCTION: Hepatitis B virus disease is a global acute and chronic communicable disease. Mother-to-child transmission is the reason for high carrier rates. Unvaccinated newborns infected through mother-to-child transmission are at >95% risk of developing chronic hepatitis B virus disease. Vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Demissie, Mebratu, Weldekidan, Haregwa Asnake, Yosef, Yirgalem, Sori, Seboka Abebe, Tsega, Daniel, Jiru, Hirut Dinku, Derribow, Aberash Beyene, Tetema, Mesfin Difer, Jima, Gudeta Beriso, Zeleke, Fentahun Temene, Endeshew, Fikremariam, Abeje, Seblework
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345928/
https://www.ncbi.nlm.nih.gov/pubmed/37457619
http://dx.doi.org/10.1177/23779608231187258
_version_ 1785073200607002624
author Demissie, Mebratu
Weldekidan, Haregwa Asnake
Yosef, Yirgalem
Sori, Seboka Abebe
Tsega, Daniel
Jiru, Hirut Dinku
Derribow, Aberash Beyene
Tetema, Mesfin Difer
Jima, Gudeta Beriso
Zeleke, Fentahun Temene
Endeshew, Fikremariam
Abeje, Seblework
author_facet Demissie, Mebratu
Weldekidan, Haregwa Asnake
Yosef, Yirgalem
Sori, Seboka Abebe
Tsega, Daniel
Jiru, Hirut Dinku
Derribow, Aberash Beyene
Tetema, Mesfin Difer
Jima, Gudeta Beriso
Zeleke, Fentahun Temene
Endeshew, Fikremariam
Abeje, Seblework
author_sort Demissie, Mebratu
collection PubMed
description INTRODUCTION: Hepatitis B virus disease is a global acute and chronic communicable disease. Mother-to-child transmission is the reason for high carrier rates. Unvaccinated newborns infected through mother-to-child transmission are at >95% risk of developing chronic hepatitis B virus disease. Vaccination is the most effective measure to reduce the global incidence of hepatitis B virus disease. Despite the World Health Organization's target to achieve 90% of the hepatitis B vaccine birth dose by 2030, little is known about the vaccination status of exposed newborns. OBJECTIVE: The present study aimed to determine the timing of the hepatitis B vaccine birth dose in exposed newborns in Southwest Ethiopia. METHODS: An institution-based cross-sectional study was employed on 422 systematically selected exposed newborns from April 2, 2022, to August 28, 2022. A pretested, interviewer-administered questionnaire was used for data collection. Data were entered into Epi data 3.1 and exported into SPSS version 23 software for analysis. Both bivariable and multivariable binary logistic regressions were performed. Variables with a p-value <.05 at a 95% confidence interval (CI) were considered statistically significant. RESULTS: The proportion of neonates who received their first dose of the hepatitis B vaccine on time was 57 (42.5%) (95% CI: 38.3–46.1%). A higher likelihood of vaccinating their exposed newborns on time was associated with formal education (adjusted odds ratio [AOR] = 3.01, 95% CI: 2.21–7.09), four or more ANC visits (AOR = 2.33, 95% CI: 2.05–6.21), and husband engagement (AOR = 4.31, 95% CI: 2.03–6.34). CONCLUSION: The proportion of timely initiation of the hepatitis B vaccine birth dose in Southwest Ethiopia was low. Thus, strengthening health education on the hepatitis B vaccine, encouraging women to have at least four ANC visits, and encouraging male involvement help improve the timely administration of the hepatitis B vaccine.
format Online
Article
Text
id pubmed-10345928
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-103459282023-07-15 Timing of Hepatitis B Vaccine Birth Dose in Exposed Newborns, Southwest Ethiopia: A Cross-Sectional Study Demissie, Mebratu Weldekidan, Haregwa Asnake Yosef, Yirgalem Sori, Seboka Abebe Tsega, Daniel Jiru, Hirut Dinku Derribow, Aberash Beyene Tetema, Mesfin Difer Jima, Gudeta Beriso Zeleke, Fentahun Temene Endeshew, Fikremariam Abeje, Seblework SAGE Open Nurs Perinatal Nursing and Midwifery INTRODUCTION: Hepatitis B virus disease is a global acute and chronic communicable disease. Mother-to-child transmission is the reason for high carrier rates. Unvaccinated newborns infected through mother-to-child transmission are at >95% risk of developing chronic hepatitis B virus disease. Vaccination is the most effective measure to reduce the global incidence of hepatitis B virus disease. Despite the World Health Organization's target to achieve 90% of the hepatitis B vaccine birth dose by 2030, little is known about the vaccination status of exposed newborns. OBJECTIVE: The present study aimed to determine the timing of the hepatitis B vaccine birth dose in exposed newborns in Southwest Ethiopia. METHODS: An institution-based cross-sectional study was employed on 422 systematically selected exposed newborns from April 2, 2022, to August 28, 2022. A pretested, interviewer-administered questionnaire was used for data collection. Data were entered into Epi data 3.1 and exported into SPSS version 23 software for analysis. Both bivariable and multivariable binary logistic regressions were performed. Variables with a p-value <.05 at a 95% confidence interval (CI) were considered statistically significant. RESULTS: The proportion of neonates who received their first dose of the hepatitis B vaccine on time was 57 (42.5%) (95% CI: 38.3–46.1%). A higher likelihood of vaccinating their exposed newborns on time was associated with formal education (adjusted odds ratio [AOR] = 3.01, 95% CI: 2.21–7.09), four or more ANC visits (AOR = 2.33, 95% CI: 2.05–6.21), and husband engagement (AOR = 4.31, 95% CI: 2.03–6.34). CONCLUSION: The proportion of timely initiation of the hepatitis B vaccine birth dose in Southwest Ethiopia was low. Thus, strengthening health education on the hepatitis B vaccine, encouraging women to have at least four ANC visits, and encouraging male involvement help improve the timely administration of the hepatitis B vaccine. SAGE Publications 2023-07-12 /pmc/articles/PMC10345928/ /pubmed/37457619 http://dx.doi.org/10.1177/23779608231187258 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Perinatal Nursing and Midwifery
Demissie, Mebratu
Weldekidan, Haregwa Asnake
Yosef, Yirgalem
Sori, Seboka Abebe
Tsega, Daniel
Jiru, Hirut Dinku
Derribow, Aberash Beyene
Tetema, Mesfin Difer
Jima, Gudeta Beriso
Zeleke, Fentahun Temene
Endeshew, Fikremariam
Abeje, Seblework
Timing of Hepatitis B Vaccine Birth Dose in Exposed Newborns, Southwest Ethiopia: A Cross-Sectional Study
title Timing of Hepatitis B Vaccine Birth Dose in Exposed Newborns, Southwest Ethiopia: A Cross-Sectional Study
title_full Timing of Hepatitis B Vaccine Birth Dose in Exposed Newborns, Southwest Ethiopia: A Cross-Sectional Study
title_fullStr Timing of Hepatitis B Vaccine Birth Dose in Exposed Newborns, Southwest Ethiopia: A Cross-Sectional Study
title_full_unstemmed Timing of Hepatitis B Vaccine Birth Dose in Exposed Newborns, Southwest Ethiopia: A Cross-Sectional Study
title_short Timing of Hepatitis B Vaccine Birth Dose in Exposed Newborns, Southwest Ethiopia: A Cross-Sectional Study
title_sort timing of hepatitis b vaccine birth dose in exposed newborns, southwest ethiopia: a cross-sectional study
topic Perinatal Nursing and Midwifery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345928/
https://www.ncbi.nlm.nih.gov/pubmed/37457619
http://dx.doi.org/10.1177/23779608231187258
work_keys_str_mv AT demissiemebratu timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT weldekidanharegwaasnake timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT yosefyirgalem timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT sorisebokaabebe timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT tsegadaniel timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT jiruhirutdinku timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT derribowaberashbeyene timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT tetemamesfindifer timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT jimagudetaberiso timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT zelekefentahuntemene timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT endeshewfikremariam timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy
AT abejeseblework timingofhepatitisbvaccinebirthdoseinexposednewbornssouthwestethiopiaacrosssectionalstudy